2765081-21-6

Product Details:

CasNo： 2765081-21-6

Molecular Formula： C44H58N8O5S

Appearance： White to almost White Powder

Packing： Aluminium bag

Throughput： 100KG/Month

Purity： 99%

Daraxonrasib (RASONQUE™, RMC‑6236) Daraxonrasib is an oral, potent RAS(ON) multi‑selective non‑covalent tri‑complex inhibitor of the RAS GTPase family. It binds to cyclophilin A to form a binary complex, which then engages the active GTP‑bound conformation of RAS protein. This tri‑complex blocks the interaction between RAS and its downstream effectors and accelerates GTP hydrolysis, switching RAS into its inactive GDP‑bound form. It suppresses signalling of a broad spectrum of RAS variants including KRAS, NRAS and HRAS with G12, G13 and Q61 mutations, leading to tumour growth inhibition and apoptosis.

It received US FDA approval in August 2026 for the treatment of adult patients with metastatic pancreatic adenocarcinoma (mPDAC) who have received at least one prior systemic therapy or are not candidates for multi‑agent systemic therapy. It has obtained both Breakthrough Therapy Designation and Orphan Drug Designation from FDA for pancreatic cancer. Global Phase 3 registrational trials are ongoing for RAS‑mutant non‑small cell lung cancer and colorectal carcinoma. The approved dosage forms are 100 mg and 150 mg film‑coated tablets for once‑daily oral administration. Common adverse events include rash, diarrhoea, stomatitis, nausea, vomiting and fatigue. Interstitial lung disease / pneumonitis is an important warning risk. It is not scheduled under DEA controlled substance lists.Revolution...